Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects

This study has been completed.
Sponsor:
Collaborators:
Triligent International
Tegra Analytics
Information provided by (Responsible Party):
St. Renatus, LLC
ClinicalTrials.gov Identifier:
NCT01701505
First received: October 2, 2012
Last updated: December 6, 2012
Last verified: December 2012

October 2, 2012
December 6, 2012
October 2012
October 2012   (final data collection date for primary outcome measure)
Completion of the Study Dental Procedure without need for rescue by injection of local anesthetic(yes/no) [ Time Frame: at 14 minutes with a 3 minute window ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01701505 on ClinicalTrials.gov Archive Site
  • Incidence of adverse events (AEs) by age and dose. [ Time Frame: from baseline to 24 hours following drug administration ] [ Designated as safety issue: Yes ]
  • Naris examination (NE) to assess reactions to the study drug. [ Time Frame: At 120 Minutes ] [ Designated as safety issue: Yes ]
    The principal investigator will perform a visual inspection to note any abnormalities
  • Systolic Blood Pressure [ Time Frame: At 12 minutes and 120 minutes ] [ Designated as safety issue: Yes ]
  • Diastolic Blood Pressure [ Time Frame: At 12 minutes and 120 minutes ] [ Designated as safety issue: Yes ]
  • Heart Rate [ Time Frame: At 12 minutes and 120 minutes ] [ Designated as safety issue: Yes ]
  • Oxygen Saturation [ Time Frame: At 12 minutes and 120 minutes ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects
A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects

The purpose of this study is to assess the efficacy and safety of intranasally administered Kovacaine Mist for anesthetizing maxillary teeth in pediatric subjects.

This is a single-center, open-label, randomized, parallel-groups, dose-ranging study to assess the efficacy and safety of intranasally administered Kovacaine Mist for anesthetizing maxillary teeth in pediatric subjects.

The study will employ an open-label design to determine the lowest effective doses (LEDs), and assess the safety and efficacy of Kovacaine Mist administered intranasally for inducing pulpal anesthesia of maxillary primary teeth numbers A to J and maxillary permanent teeth numbers 4 to 13 (maxillary right second premolar to maxillary left second premolar) sufficient to allow completion of the Study Dental Procedure, and will be carried out in healthy children of either sex between the ages of 3 and 17 years, inclusive.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Anesthesia
  • Drug: 400uL of Kovacaine Mist
    2 unilateral intranasal sprays of 200uL each.
    Other Name: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
  • Drug: 200uL of Kovacaine Mist
    2 unilateral intranasal sprays of 100uL each.
    Other Name: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
  • Drug: 120uL of Kovacaine Mist
    2 unilateral intranasal sprays of 60uL each.
    Other Name: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
  • Experimental: Kovacaine Mist High Dose
    400uL of Kovacaine Mist, as 2 sprays of 200uL.
    Intervention: Drug: 400uL of Kovacaine Mist
  • Experimental: Kovacaine Mist Mid Dose
    200uL of Kovacaine Mist, as 2 sprays of 100uL.
    Intervention: Drug: 200uL of Kovacaine Mist
  • Experimental: Kovacaine Mist Low Dose
    120uL of Kovacaine Mist, as 2 sprays of 60uL.
    Intervention: Drug: 120uL of Kovacaine Mist
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
October 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female 3-17 years of age inclusive.
  • Need for an operative restorative dental procedure on a single vital maxillary primary tooth (#A to J) or permanent tooth (#4 to13), other than a maxillary permanent first, second or third molar, requiring local anesthesia with an expected treatment duration not exceeding 60 minutes.
  • Normal lip, nose, eyelid, and cheek sensation.
  • Accompanied and/or represented by a parent or guardian able to comprehend and sign the informed consent document.
  • If age 8 and above, able to understand and provide informed assent.
  • Patient or parent/guardian able to communicate with the investigator and comply with the requirements of the protocol.
  • Patency of the naris ipsilateral to the tooth undergoing the Study Dental Procedure.
  • Minimum weight: Subjects in Cohorts A and B (age 6 and above) must weigh at least 20kg (44 lb.). Subjects in Cohort C (age 3 and above) must weigh at least 10kg (22 lb.).

Exclusion Criteria:

  • Dental care requiring a local anesthetic within the 24 hours prior to anticipated study participation.
  • History of allergy to or intolerance of tetracaine, benzyl alcohol, other ester local anesthetics, or para-aminobenzoic acid (as found in PABA-containing sunscreen).
  • History of allergy or hypersensitivity to lidocaine, oxymetazoline, epinephrine, or sulfite preservatives.
  • Use of a monoamine oxidase inhibitor within the 3 weeks preceding study entry.
  • Nursing, pregnant, suspected of being pregnant, or trying to become pregnant. (Females of child-bearing potential will be required to take a urine pregnancy test on the day of, but prior to, study drug administration to rule out pregnancy.)
  • Inadequately controlled thyroid disease of any type.
  • Use of any investigational drug (including Kovacaine Mist) and/or participation in any clinical trial within 30 days of study participation.
  • Frequent nose bleeds (≥ 5 per month).
  • Anticipated need for use of oxymetazoline or phenylephrine nasal spray, nasal irrigation, or other nasal or oral decongestant on the day of the study procedure.
  • History of congenital or idiopathic methemoglobinemia.
  • Clinically relevant history of sinus/nasal surgery, recent epistaxis, nasal congestion or sinus infections, or use of a "sinus medication" within the 48 hours prior to anticipated study participation.
  • History of alcoholism and/or drug abuse.
  • Pulpal pathology in the index tooth.
  • Anticipated need for use of nitrous oxide before or during the Study Dental Procedure.
  • Any chronic or currently uncontrolled psychogenic, neurological, endocrine, pulmonary, cardiovascular, renal, gastrointestinal or hepatic disease or condition with manifestations that might confound interpretation of study results or make receipt of study medication a source of risk for adverse outcome.
  • Fever defined as body temperature ≥100° (37°C) on the day of and prior to study drug administration.
Both
3 Years to 17 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01701505
SR 2-03
No
St. Renatus, LLC
St. Renatus, LLC
  • Triligent International
  • Tegra Analytics
Study Director: Paul A. Moore, DMD/PhD/MPH University of Pittsburgh
St. Renatus, LLC
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP